safusidenib
safusidenib: developed by 1 company · 3 clinical trials tracked.
safusidenib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could safusidenib → NUVB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nuvation Bio Inc. (NUVB) Grade 2 IDH1-mutant Glioma; Grade 2 Glioma (Astrocytoma or O… | Phase 3 |
Clinical Trials (3)
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Primary endpoint: Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
Primary endpoint: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0
A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
Primary endpoint: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs)
Frequently asked questions
Who is developing safusidenib?
safusidenib is being developed by Nuvation Bio Inc..
How many clinical trials involve safusidenib?
BioSniper tracks 3 clinical trials involving safusidenib.